Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Pipeline Review, H1 2017

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0773TDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Pipeline Review, H1 2017

Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The latest report Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Pipeline Review, H1 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 8 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Lymphoma, Melanoma, Advanced Malignancy, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Kidney Cancer (Renal Cell Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma and Renal Cell Carcinoma.

Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics and enlists all their major and minor projects

The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Overview

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Companies Involved in Therapeutics Development

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Crescendo Biologics Ltd

Enumeral Biomedical Holdings Inc

GlaxoSmithKline Plc

Icell Kealex Therapeutics

Incyte Corp

MacroGenics Inc

Merck & Co Inc

Novartis AG

Prima BioMed Ltd

Regeneron Pharmaceuticals Inc

Sutro Biopharma Inc

Symphogen A/S

Tesaro Inc

Trellis Bioscience Inc

Xencor Inc

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Drug Profiles

BI-754111-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986016-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENUM-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IKT-203-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-731-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-761-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAG-525-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGD-013-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4280-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG-3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2810 + REGN-3767-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3767-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-7117-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-033-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Dormant Products

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)-Product Development Milestones

Featured News & Press Releases

May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

Jan 03, 2017: Prima Announces New Product Candidate IMP761-A LAG-3 Agonist Antibody

Aug 25, 2016: European Patent Grants for IMP731 Antibody

Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016

Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates

Jan 27, 2016: US Patent Grants for IMP731 Antibody

Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program

May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Boehringer Ingelheim GmbH, H1 2017

Pipeline by Bristol-Myers Squibb Company, H1 2017

Pipeline by Crescendo Biologics Ltd, H1 2017

Pipeline by Enumeral Biomedical Holdings Inc, H1 2017

Pipeline by GlaxoSmithKline Plc, H1 2017

Pipeline by Icell Kealex Therapeutics, H1 2017

Pipeline by Incyte Corp, H1 2017

Pipeline by MacroGenics Inc, H1 2017

Pipeline by Merck & Co Inc, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Prima BioMed Ltd, H1 2017

Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Pipeline by Sutro Biopharma Inc, H1 2017

Pipeline by Symphogen A/S, H1 2017

Pipeline by Tesaro Inc, H1 2017

Pipeline by Trellis Bioscience Inc, H1 2017

Pipeline by Xencor Inc, H1 2017

Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Crescendo Biologics Ltd, Enumeral Biomedical Holdings Inc, GlaxoSmithKline Plc, Icell Kealex Therapeutics, Incyte Corp, MacroGenics Inc, Merck & Co Inc, Novartis AG, Prima BioMed Ltd, Regeneron Pharmaceuticals Inc, Sutro Biopharma Inc, Symphogen A/S, Tesaro Inc, Trellis Bioscience Inc, Xencor Inc

select a license

Single User License
USD 3500 INR 227675
Site License
USD 7000 INR 455350
Corporate User License
USD 10500 INR 683025

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com